Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan A Randomized, Double-Blind, Multicenter Study

被引:16
|
作者
Hong, Bum-Kee [2 ]
Park, Chang Gyu [3 ]
Kim, Ki Sik [4 ]
Yoon, Myeong Ho [5 ]
Yoon, Ho Joong [6 ]
Yoon, Jeong Han [7 ]
Yang, Joo Young [8 ]
Choi, Young Jin [9 ]
Cho, Seung Yun [1 ]
机构
[1] Yonsei Univ, Coll Med, Cardiovasc Hosp, Div Cardiol, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Ctr Heart, Seoul, South Korea
[3] Korea Univ, Guro Hosp, Div Cardiol, Seoul, South Korea
[4] Daegu Catholic Univ, Med Ctr, Div Cardiol, Taegu, South Korea
[5] Ajou Univ, Med Ctr, Div Cardiol, Suwon, South Korea
[6] Catholic Univ, Seoul St Mary Hosp, Div Cardiol, Seoul, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Div Cardiol, Songnam, Gyeonggi Do, South Korea
[8] Ilsan Hosp, Natl Hlth Insurance Corp, Dept Cardiol, Ilsan, South Korea
[9] Hallym Univ, Med Ctr, Hanging Sacred Heart Hosp, Div Cardiol, Seoul, South Korea
关键词
AMLODIPINE/VALSARTAN COMBINATION THERAPY; RECEPTOR ANTAGONIST; BLOOD-PRESSURE; PHARMACOKINETICS; TOLERABILITY; PREVENTION; VALSARTAN; OUTCOMES; TRIAL;
D O I
10.2165/11597410-000000000-00000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7 +/- 7.0 and 3.2 +/- 7.9 mmHg), which was significantly greater in the amlodipine/losartan 5 mg/100 mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5 mg/100 mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100 mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5 mg/100 mg group versus the losartan 100 mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5 mg/100 mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100 mg in Korean patients with essential hypertension inadequately controlled on losartan 100 mg.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 50 条
  • [41] The efficacy and safety of fixed-dose combination of amlodipine/benazepril in Chinese essential hypertensive patients not adequately controlled with benazepril monotherapy: a multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial
    Yan, Pingping
    Fan, Weihu
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2014, 36 (04) : 268 - 274
  • [42] Additive effects of losartan combined with simvastatin on vasomotion and inflammation in hypercholesterolemic and hypertensive patients: A randomized, double-blind, placebo-controlled, crossover study
    Koh, KK
    Han, SH
    Ahn, JY
    Chung, WJ
    Choi, IS
    Shin, EK
    CIRCULATION, 2003, 108 (17) : 631 - 631
  • [43] A double-blind, dose-response study of losartan in hypertensive children (vol 18, pg 183, 2005)
    Shahinfar, S.
    Cano, F.
    Soffer, B. A.
    Ahmed, T.
    Santoro, E. P.
    Zhang, Z.
    Gleim, G.
    Miller, K.
    Vogt, B.
    Blumer, J.
    Briazgounov, I.
    AMERICAN JOURNAL OF HYPERTENSION, 2006, 19 (06) : 658 - 658
  • [44] The safety and efficacy of losartan/hydrochlorothiazide in the treatment of patients with severe hypertension; A multicenter study
    Aurup, P
    Smith, RD
    Snavely, D
    Oparil, S
    JOURNAL OF HYPERTENSION, 2000, 18 : S99 - S99
  • [45] Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
    Choi, YoonJung
    Lee, SeungHwan
    Cho, Sang-Min
    Kang, Won-Ho
    Nam, Kyu-Yeol
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3021 - 3028
  • [46] Comparison of the Efficacy and Safety of Single-Pill Fixed-Dose Combinations of Losartan/Hydrochlorothiazide and Valsartan/Hydrochlorothiazide in Patients with Hypertension (SALT-VAT Study)
    Shiga, Yuhei
    Miura, Shin-ichiro
    Morii, Joji
    Kuwano, Takashi
    Mitsutake, Ryoko
    Uehara, Yoshinari
    Inoue, Asao
    Saku, Keijiro
    INTERNAL MEDICINE, 2011, 50 (21) : 2477 - 2483
  • [47] Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria
    Kohlmann, Osvaldo, Jr.
    Roca-Cusachs, Alejandro
    Laurent, Stephane
    Schmieder, Roland E.
    Wenzel, Rene R.
    Fogari, Roberto
    ADVANCES IN THERAPY, 2009, 26 (03) : 313 - 324
  • [48] Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria
    Osvaldo Kohlmann
    Alejandro Roca-Cusachs
    Stéphane Laurent
    Roland E. Schmieder
    René R. Wenzel
    Roberto Fogari
    Advances in Therapy, 2009, 26
  • [49] Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial
    Khodaei, Behzad
    Nasimi, Maryam
    Nassireslami, Ehsan
    Seyedpour, Simin
    Rahmati, Javad
    Abianeh, Shahriar Haddady
    Khiavi, Farhad Motavalli
    AESTHETIC PLASTIC SURGERY, 2022, 46 (05) : 2580 - 2587
  • [50] Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial
    Behzad Khodaei
    Maryam Nasimi
    Ehsan Nassireslami
    Simin Seyedpour
    Javad Rahmati
    Shahriar Haddady Abianeh
    Farhad Motavalli Khiavi
    Aesthetic Plastic Surgery, 2022, 46 : 2580 - 2587